FBL MTX
Alternative Names: FBL-MTX; Folate-based liposomes based methotrexate - SOLFARCOSLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator SOLFARCOS - Pharmaceutical and Cosmetic Solutions
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Portugal (IV, Injection)
- 24 Jul 2024 Phase-II clinical trials in Rheumatoid arthritis in Portugal (SC, Injection) (NCT06565273)
- 19 Oct 2021 SOLFARCOS completes a phase I trial in Rheumatoid arthritis (In volunteers) in Portugal (IV) (NCT05117593)